Triple-Drug attack before lung surgery shows promise in early trial

NCT ID NCT07567326

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests whether adding a PCSK-9 inhibitor (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 participants will receive either adebrelimab or retlirafusp alfa plus recaticimab and chemo, then undergo surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab or retlirafusp alfa (SHR-1701) plus recaticimab and chemotherapy
What this could lead to: If successful, this combination could improve the chance of eliminating all cancer before surgery and potentially extend survival for people with resectable non-small cell lung cancer.
What could go wrong: This is an early phase 2 trial with only 78 participants, so results may not apply to everyone. Adding more drugs also raises the risk of side effects, and the benefit over standard treatment is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.